Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter

IMPACT FACTOR 2017: 3.556

CiteScore 2017: 2.34

SCImago Journal Rank (SJR) 2017: 1.114
Source Normalized Impact per Paper (SNIP) 2017: 1.188

See all formats and pricing
More options …
Volume 55, Issue 10


Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry

Roberta Pacifici / Emilia Marchei / Francesco Salvatore
  • Agenzia Industrie e Difesa, Stabilimento Chimico Farmaceutico Militare (Military Pharmaceutical Chemical Works of Florence) Florence, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Luca Guandalini
  • Agenzia Industrie e Difesa, Stabilimento Chimico Farmaceutico Militare (Military Pharmaceutical Chemical Works of Florence) Florence, Italy
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Francesco Paolo Busardò
  • Corresponding author
  • DipFMS, Unit of Forensic Toxicology (UoFT), Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza, University of Rome 336, Viale Regina Elena, 00161 Rome, Italy, Phone: +39-06-49912622, Fax: +39-06-49902016
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Simona Pichini
Published Online: 2017-02-16 | DOI: https://doi.org/10.1515/cclm-2016-1060



Cannabis has been used since ancient times to relieve neuropathic pain, to lower intraocular pressure, to increase appetite and finally to decrease nausea and vomiting. The combination of the psychoactive cannabis alkaloid Δ9-tetrahydrocannabinol (THC) with the non-psychotropic alkaloids cannabidiol (CBD) and cannabinol (CBN) demonstrated a higher activity than THC alone. The Italian National Institute of Health sought to establish conditions and indications on how to correctly use nationally produced cannabis to guarantee therapeutic continuity in individuals treated with medical cannabis.


The evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil was conducted using an easy and fast ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) assay.


Extraction efficiency of oil was significantly higher than that of water with respect to the different cannabinoids. This was especially observed in the case of the pharmacologically active THC, CBD and their acidic precursors. Fifteen minutes boiling was sufficient to achieve the highest concentrations of cannabinoids in the cannabis tea solutions. At ambient temperature, a significant THC and CBD decrease to 50% or less of the initial concentration was observed over 3 and 7 days, respectively. When refrigerated at 4 °C, similar decreasing profiles were observed for the two compounds. The cannabinoids profile in cannabis oil obtained after pre-heating the flowering tops at 145 °C for 30 min in a static oven resulted in a complete decarboxylation of cannabinoid acids CBDA and THCA-A. Nevertheless, it was apparent that heat not only decarboxylated acidic compounds, but also significantly increased the final concentrations of cannabinoids in oil. The stability of cannabinoids in oil samples was higher than that in tea samples since the maximum decrease (72% of initial concentration) was observed in THC coming from unheated flowering tops at ambient temperature. In the case of the other cannabinoids, at ambient and refrigerated temperatures, 80%–85% of the initial concentrations were measured up to 14 days after oil preparation.


As the first and most important aim of the different cannabis preparations is to guarantee therapeutic continuity in treated individuals, a strictly standardized preparation protocol is necessary to assure the availability of a homogeneous product of defined stability.

Keywords: cannabinoids recovery; cannabinoids stability; cannabis oil; cannabis tea; medical cannabis; UHPLC-MS/MS


  • 1.

    Website: World Drug Report 2016. Available at: https://www.unodc.org/doc/wdr2016/WORLD_DRUG_REPORT_2016_web.pdf. Accessed 21 Nov 2016.

  • 2.

    Pacula RL, Jacobson M, Maksabedian EJ. In the weeds: a baseline view of cannabis use among legalizing states and their neighbours. Addiction 2016;111:973–80.Web of ScienceGoogle Scholar

  • 3.

    Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. J Am Med Assoc 2015;313:2456–73.Web of ScienceGoogle Scholar

  • 4.

    Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci 2007;9:413–30.Google Scholar

  • 5.

    Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006;66:234–46.Google Scholar

  • 6.

    Muller-Vahl KR. Cannabinoids reduce symptoms of Tourette’s syndrome. Expert Opin Pharmacother 2003;4:1717–25.Google Scholar

  • 7.

    Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease. Neurobiol Dis 2005;19:96–107.Google Scholar

  • 8.

    Novack GD. Cannabinoids for treatment of glaucoma. Curr Opin Ophthalmol 2016;27:146–50.Web of ScienceCrossrefGoogle Scholar

  • 9.

    Abrams DI, Guzman M. Cannabis in cancer care. Clin Pharmacol Ther 2015;97:575–86.Web of ScienceCrossrefGoogle Scholar

  • 10.

    Website: Decreto 9 novembre 2015: Funzioni di Organismo statale per la cannabis previsto dagli articoli 23 e 28 della convenzione unica sugli stupefacenti del 1961, come modificata nel 1972. Available at: http://www.gazzettaufficiale.it/eli/id/2015/11/30/15A08888/sg;jsessionid=p1rnwNujUKlqQ5azhAQ95A__.ntc-as3-guri2a. Accessed 6 Dec 2016.

  • 11.

    Verhoeckx KC, Korthout HA, van Meeteren-Kreikamp AP, Ehlert KA, Wang M, van der Greef J, et al. Unheated cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol 2006;6:656–65.CrossrefGoogle Scholar

  • 12.

    Ruhaak LR, Felth J, Karlsson PC, Rafter JJ, Verpoorte R, Bohlin L. Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biol Pharm Bull 2011;34:774–8.Web of ScienceGoogle Scholar

  • 13.

    Moldzio R, Pacher T, Krewenka C, Kranner B, Novak J, Duvigneau JC, et al. Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP(+) affected murine mesencephalic cultures. Phytomedicine 2012;19:819–24.Web of ScienceGoogle Scholar

  • 14.

    Rock EM, Kopstick RL, Limebeer CL, Parker LA. Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. Br J Pharmacol 2013;170:641–8.Web of ScienceGoogle Scholar

  • 15.

    Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, Duncan M, et al. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 2013;168:1456–70.Web of ScienceGoogle Scholar

  • 16.

    Takeda S, Okazaki H, Ikeda E, Abe S, Yoshioka Y, Watanabe K, et al. Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells. J Toxicol Sci 2014;39:711–6.CrossrefWeb of ScienceGoogle Scholar

  • 17.

    Rock EM, Limebeer CL, Parker LA. Effect of combined doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague- Dawley) models of conditioned gaping. Psychopharmacology 2015;232:4445–4.Web of ScienceGoogle Scholar

  • 18.

    Brierley DI, Samuels J, Duncan M, Whalley BJ, Williams CM. Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea. Psychopharmacology 2016;233:243–54.Web of ScienceGoogle Scholar

  • 19.

    Christophersen AS. Tetrahydrocannabinol stability in whole blood: plastic versus glass containers. J Anal Toxicol 1986;10:129–31.CrossrefGoogle Scholar

  • 20.

    Ventura M, Pichini S, Ventura R, Leal S, Zuccaro P, Pacifici R, et al. Stability of drugs of abuse in oral fluid collection devices with purpose of external quality assessment schemes. Ther Drug Monit 2009;31:277–80.CrossrefWeb of ScienceGoogle Scholar

  • 21.

    Website: Recommended methods for the identification and analysis of cannabis and cannabis products 2009. Available at http://www.unodc.org/documents/scientific/ST-NAR-40-Ebook.pdf Accessed 6 december, 2016).

  • 22.

    Romano LL, Hazekamp A. Cannabis oil: chemical evaluation of an upcoming cannabis-based medicine. Cannabinoids 2013;1:1–11.Google Scholar

  • 23.

    Website: FDA Pharmaceutical Quality/CMC; Guidance for Industry, Analytical Procedures and Methods Validation for Drugs and Biologics, US Department of Health and Human Services, Food and Drug Administration. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm386366.pdf. Accessed 18 Nov 2016.

  • 24.

    Website: ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology, 2005. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf. Accessed 18 Nov 2016.

  • 25.

    Hazekamp A, Bastola K, Rashidi H, Bender J, Verpoorte R. Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea. J Ethnopharmacol 2007;233:85–90.Web of ScienceGoogle Scholar

  • 26.

    Veress T, Szanto JI, Leisztner L. Determination of cannabinoid acids by high-performance liquid chromatography of their neutral derivatives formed thermal decarboxylation. J Chrom A 1990;520:339–47.Google Scholar

  • 27.

    Citti C, Ciccarella G, Braghiroli D, Parenti C, Vandelli MA, Cannazza G. Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. J Pharm Biomed Anal 2016;128:201–9.Web of ScienceGoogle Scholar

  • 28.

    Russo EB, McPartland JM. Cannabis is more than simply delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 2003;165:431–2.Google Scholar

About the article

Corresponding author: Dr. Francesco Paolo Busardò, MD, MSc, PhD, DipFMS, Unit of Forensic Toxicology (UoFT), Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza, University of Rome 336, Viale Regina Elena, 00161 Rome, Italy, Phone: +39-06-49912622, Fax: +39-06-49902016, E-mail:

Received: 2016-11-21

Accepted: 2016-12-29

Published Online: 2017-02-16

Published in Print: 2017-08-28

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: Funded by the project: “Implementazione dei Sistemi di Sorveglianza sul disturbo da gioco d’azzardo e sull’uso medico della cannabis sul territorio Nazionale” by the Italian Ministry of Health.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 55, Issue 10, Pages 1555–1563, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2016-1060.

Export Citation

©2017 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Riccardo Deidda, Hermane T. Avohou, Roberto Baronti, Pier Luigi Davolio, Benedetta Pasquini, Massimo Del Bubba, Cédric Hubert, Philippe Hubert, Serena Orlandini, and Sandra Furlanetto
Journal of Pharmaceutical and Biomedical Analysis, 2019
Sebastiano Barco, Carmen Fucile, Luca Manfredini, Elisa De Grandis, Marcella Gherzi, Antonietta Martelli, Gino Tripodi, Francesca Mattioli, and Giuliana Cangemi
Bioanalysis, 2018
Sarah S. Stith, Jacob M. Vigil, Franco Brockelman, Keenan Keeling, and Branden Hall
Frontiers in Pharmacology, 2018, Volume 9
Lanfranco Pellesi, Manuela Licata, Patrizia Verri, Daniele Vandelli, Federica Palazzoli, Filippo Marchesi, Maria Michela Cainazzo, Luigi Alberto Pini, and Simona Guerzoni
European Journal of Clinical Pharmacology, 2018
Vladimiro Cardenia, Tullia Gallina Toschi, Simona Scappini, Rosamaria Cristina Rubino, and Maria Teresa Rodriguez-Estrada
Journal of Food and Drug Analysis, 2018
Radmila Pavlovic, Giorgio Nenna, Lorenzo Calvi, Sara Panseri, Gigliola Borgonovo, Luca Giupponi, Giuseppe Cannazza, and Annamaria Giorgi
Molecules, 2018, Volume 23, Number 5, Page 1230
Chiara Carcieri, Cristina Tomasello, Marco Simiele, Amedeo De Nicolò, Valeria Avataneo, Luca Canzoneri, Jessica Cusato, Giovanni Di Perri, and Antonio D'Avolio
Journal of Pharmacy and Pharmacology, 2017
Cinzia Citti, Daniela Braghiroli, Maria Angela Vandelli, and Giuseppe Cannazza
Journal of Pharmaceutical and Biomedical Analysis, 2017

Comments (0)

Please log in or register to comment.
Log in